Substance P (SP) promotes cholangiocyte growth during cholestasis by activating its receptor, NK1R. SP is a proteolytic product of tachykinin (Tac1) and is deactivated by membrane metalloendopeptidase (MME). This study aimed to evaluate the functional role of SP in the regulation of cholangiocarcinoma (CCA) growth. NK1R, Tac1, and MME expression and SP secretion were assessed in human CCA cells and nonmalignant cholangiocytes. The proliferative effects of SP (in the absence/presence of the NK1R inhibitor, L-733,060) and of L-733,060 were evaluated. In vivo, the effect of L-733,060 treatment or MME overexpression on tumor growth was evaluated by using a xenograft model of CCA in nu/nu nude mice.
tween cell proliferation and apoptosis (8) . Cholangiocarcinoma (CCA) results from the malignant transformation of cholangiocytes (33) . The pathogenesis of CCA is linked to chronic biliary inflammation, which occurs in cholangiopathies such as primary sclerosing cholangitis (8, 36) . CCA is frequently diagnosed at advanced stages, resulting in limited treatment options and a high mortality (33) . In addition, CCA responds poorly to both surgical resection and standard chemotherapy (33) . With limited treatment strategies and reports of increasing incidence and prevalence of CCA worldwide (40) , it is critical to gain a better understanding of the factors regulating cholangiocyte growth and neoplastic transformation.
Recent studies have shown that proliferating cholangiocytes can serve as a neuroendocrine compartment during the progression of liver diseases by secreting and responding to a number of hormones and neuropeptides (such as serotonin, melatonin, and histamine), thereby contributing to the autocrine and paracrine pathways modulating liver inflammation and fibrosis (3, 14, 22) . The majority of intrinsic hepatic nerves are associated with the vascular and biliary systems (43, 51) . Two afferent nerve pathways have been identified in the liver: the vagal afferent nerve pathway and the spinal afferent nerve pathway (dorsal root ganglion) (51) . Sensory nerves also possess efferent functions that are mediated by the release of sensory neuropeptides [i.e., calcitonin gene-related peptide (CGRP) and substance P (SP)] from their peripheral terminals in tissues they innervate, thereby regulating cellular functions independent of sensation (24) .
We have previously shown that knockout of ␣-CGRP and neurokinin-1 receptor (NK1R) reduces biliary hyperplasia in mice with extrahepatic cholestasis (19, 20) . SP is a member of the tachykinin peptide family, which is composed of six members to date: SP, neurokinin A, neurokinin B, neuropeptide K, neuropeptide ␥, and hemokinin (39) . SP is released from sensory nerve endings at the level of both the spinal cord and peripheral tissues (1) . SP is also expressed by nonneuronal cells such as human endothelial cells, immune, and inflammatory cells (35) . The tachykinin receptors family consists of three types of G protein-coupled receptors: NK1, NK2, and NK3. SP preferentially binds and signals through the NK1 receptor (1) . The NK1 receptor is expressed in the central and peripheral nervous system and is also widely distributed in a number of cell types, including vascular endothelial and immune cells, contributing to the connections between the ner-vous system and peripheral organ system (35, 39) . Previous research in our team supports these extrasensory functions as the knockout of ␣-CGRP and NK1R reduce biliary hyperplasia in mice with extrahepatic cholestasis, giving support that CGRP and SP may have the capability to induce biliary hyperplasia (19, 20) . SP synthesis is regulated by the expression of tachykinin (Tac1, the gene encoding SP) and membrane metalloendopeptidase (MME), the enzymes responsible for the synthesis and degradation of SP, respectively (11, 47) . No information exists regarding the autocrine and paracrine role of SP in the regulation of CCA growth.
Given the observation that CCAs display neuroendocrine phenotypes (2), the aims of our study were to demonstrate that 1) CCA and nonmalignant biliary epithelial cells express NK1R; 2) SP stimulates CCA growth by a receptor-mediated mechanism in vitro; 3) there is enhanced expression of Tac1 and reduced expression of MME in CCA, leading to increased synthesis of SP 
MATERIALS AND METHODS
Materials. All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. Synthetic SP (SZ1062) and the SP EIA kit (EZ-061-05, recognizing human, rat, and mouse species) were purchased from Phoenix Pharmaceuticals (Belmont, CA). The rabbit polyclonal antibody (NA4300-0100) and the blocking peptide (neurokinin 1 receptor rat COOH-terminal pentadecapeptide, as negative control, NP1442-0100) for NK1R were purchased from Biomol International (Plymouth Meeting, PA). The NK1R antagonist (L-733,060) (45) was purchased from Sigma-Aldrich. The mouse monoclonal antibody (ab34199) to CD10 was purchased from Abcam (Cambridge, MA). CD10 (also known as the common acute lymphocytic leukemia antigen, CALLA) is a cell surface enzyme with MME activity that inactivates a variety of biologically active peptides including SP (6) .
The selected specific primers were purchased from SABiosciences (Qiagen; Valencia, CA) and designed by using sequences with the following NCBI GenBank Accession numbers: NM_001058 (human NK1R); NM_013998 (human Tac1); NM_000902 (human MME); NM_182649 (human PCNA); NM_002276 (human CK-19); NM_003376 (human VEGF-A); and NM_002046 (human glyceraldehyde-3-phosphate dehydrogenase, GAPDH).
Human (32, 42) were acquired from Cancer Cell Repository (Tohoku University, Sendai, Japan). These cell lines were maintained at standard conditions (27) . HuCC-T1, CCLP1, and SG231 cells (from intrahepatic bile ducts) were a kind gift from Dr. A. J. Demetris (University of Pittsburgh, Pittsburgh, PA) and were cultured as described (53) . HIBEpiC cells were cultured as recommended by the supplier (14) .
Expression of NK1R in cell lines. The expression of NK1R was evaluated by immunofluorescence (14) , real-time PCR (using 1 g total RNA) (14) , immunoblots (using 10 g of protein from whole cell lysate) (14) and FACS analysis (22) in the CCA cell lines and HIBEpiC cells.
Immunofluorescence for NK1R in the selected cell lines was performed as described (14) . Following staining, cells were mounted onto microscope slides with Prolong Antifade Gold containing 4=,6-diamidino-2-phenylindole (DAPI) as a nuclear counterstain (Molecular Probes, Eugene, OR). Negative controls were also included. Sections were visualized via an Olympus IX-71 inverted confocal microscope (Tokyo, Japan).
RNA was isolated from the selected cell lines by the RNeasy Kit (Qiagen) and reverse transcribed with the Reaction Ready First Strand cDNA synthesis kit (SABiosciences, Frederick, MD). PCR reactions were used as templates for the PCR assays by using a SYBR Green PCR master mix and specific primers designed against the selected gene analyzed in the real-time thermal cycler (Agilent MX3005P Mz-ChA-1 HuH-28
HuCCT-1 thermocycler, Santa Clara, CA). A ⌬⌬CT (delta delta of the threshold cycle) analysis was performed using HIBEpiC cells as controls (14) . Data are expressed as the fold-change of relative mRNA levels Ϯ SE. Immunoblots were normalized by ␣-tubulin (the housekeeping gene). Band intensity was determined by scanning video densitometry via the phospho-imager, Storm 860 (GE Healthcare, Piscataway, NJ), and the ImageQuant TL software version 2003.02 (GE Healthcare). FACS analysis (with 20,000 events in the light scatter, SSC/SSC, acquired) for NK1R was performed in the selected cell lines by using a C6 flow cytometer and analyzed by CFlow Software (Accuri Cytometers, Ann Arbor, MI) (22) . The expression of NK1R was identified and gated on FL1-A/Count plots. The relative quantity of NK1R (mean selected protein fluorescence) was expressed as mean FL1-A (samples)/mean FL1-A (secondary antibodies only). The standard errors were calculated as (CV FL1-A) ϫ (Mean FL1-A)/SQR-(Count-1), where FL1-A is green fluorescence channel, Count is number of cells examined, CV is standard deviation, SQR is square root, and Count-1 is number of events counted as cholangiocytes (gate 1; we counted 5,000 events under gate 1 in each group to keep consistency in all groups).
Expression of Tac1 and MME and secretion of SP in CCA and normal cholangiocyte lines. We evaluated the expression of 1) the message (by real-time PCR, see above) (14); and 2) the protein for tachykinin (Tac1, the gene encoding SP) (11) and MME in CCA cell lines and HIBEpiC cells by FACS analysis, see above (41) .
CCA and HIBEpiC cells (1 ϫ 10 7 cells/ml) were incubated for 24 h at 37°C and the amount of SP released into the media was assayed by using a commercially available EIA kit according to the manufacturer's instructions.
Effect of SP on the proliferation of nonmalignant and CCA cells. The proliferation of CCA cells and HIBEpiC cells was evaluated by MTS assays (14) . Data were expressed as fold change of proliferation vs. basal. Briefly, cells were plated in a 96-well plate (7,000 cells per well) and incubated overnight at 37°C. Medium was changed to serum free and cells were further incubated for 24 h prior to stimulation. The selected CCA cell lines were stimulated with different doses (10 Ϫ6 M to 10 Ϫ12 M for 48 h) of vehicle or SP before measuring cell growth by MTS assays (14) . We also measured the effect of SP (10 Ϫ11 M for 48 h) on the proliferation of Mz-ChA-1 cells (used in the in vivo experiments) in the absence/presence of L-733,060 (25 M) (37) . In parallel, we evaluated the effect of L-733,060 treatment alone (0, 5, 10, 25, 50, and 100 M, for 48 h) (37) on the proliferation of CCA cells by MTS assays (14) . We also evaluated, by FACS analysis, the effect of L-733,060 (stimulation at 25 M for 24 and 48 h) on the cell cycle of HIBEpic and Mz-ChA-1 cells (25) .
We used human cDNA clone (OriGene Technologies, Rockville, MD) with neomycin resistance to generate and select the stable transfected Mz-ChA-1 cells overexpressing MME (5, 14) . Real-time PCR (14) was performed to determine the degree of MME overexpression in Mz-ChA-1 cells. We also evaluated the secretion of SP (by EIA kits) in Mz-MME and Mz-neg control stably transfected MzChA-1 cell lines. In the two cell lines, we evaluated cell proliferation by MTS assays (after incubation for 24, 48, 72, and 7 days) (14) .
In vivo studies in nu/nu nude mice. Eight-week-old male Balb/c nu/nu nude mice (ϳ30 g; Charles River, Wilmington, MA) were kept in a temperature-controlled environment (20 -22°C) with 12-h lightdark cycles with free access to drinking water and standard chow. All the animal experiments were conducted under protocols approved by the Scott & White and Texas A&M HSC IACUC.
Mz-ChA-1 cells (3 ϫ 10 6 ) were injected subcutaneously into the flanks of nu/nu nude mice (14) . Treatments (by intraperitoneal injections) were performed as follows: 1) mice (n ϭ 4) received 0.9% NaCl (100 l); and 2) mice (n ϭ 4) were treated with L-733,060 (10 mg/kg ip in 100 l of NaCl) (4) every other day (4). Injections were performed every other day for 52 days after tumor establishment (day 10). After 52 days, mice were anesthetized with pentobarbital sodium (50 mg/kg ip) and tissues were harvested and used for measuring the selected parameter.
In separate experiments, Mz-MME (cells stably overexpressing MME) and Mz-neg were cultured and prepared for injection into the flanks of nu/nu nude mice as described (14) . Tumor measurements began after tumor establishment (day 10) (14) . After 21 days, both groups of mice were anesthetized with pentobarbital sodium (50 mg/kg body wt ip) and tissues were harvested. Tumor parameters were measured twice a week with an electronic caliper and volume was determined as follows: tumor volume (mm 3 ) ϭ 0.5 ϫ [length (mm) ϫ width (mm) ϫ height (mm)]. The tumors harvested were used for measuring the expression of Tac1, MME, NK1R, PCNA, CK-19, and VEGF-A (an important trophic factor for CCA growth) (10) in total tumor samples by real-time PCR (14) .
Statistical analysis. All data are expressed as mean Ϯ SE. Differences between groups were analyzed by the Student's unpaired t-test when two groups were analyzed and by ANOVA when more than two groups were analyzed, followed by an appropriate post hoc test. A value of P Ͻ 0.05 was considered significant.
RESULTS

Expression of NK1R, Tac1
, and MME in biliary cell lines and secretion of SP in biliary cell lines. By immunofluorescence, all the CCA cell lines used and HIBEpiC cells showed immunoreactivity for NK1R (red); negative controls with the use of the blocking peptide for NK1R showed no reaction (Fig. 1A) . By real-time PCR, immunoblots, and FACS analysis, the expression of NK1R was observed in nonmalignant cholangiocytes as well as in all the CCA cell lines used (Fig. 1,  B-D) . By FACS analysis, we demonstrated that the expression of NK1R increased in all the CCA cells lines compared with HIBEpiC cells (Fig. 1D) .
By real-time PCR, there was increased expression of Tac1 (the gene encoding SP) (11) and decreased expression of MME mRNA in selected CCA cells used compared with HIBEpic cells (Fig. 2, A and B) . By FACS analysis, the protein expression of Tac1 increased, whereas the expression of MME decreased in all CCA cells used compared with HIBEpic (Fig.  1D) . Furthermore, all of the CCA cell lines secreted higher levels of SP compared with HIBEpiC cells (Fig. 2C) .
SP stimulates the proliferation of CCA cells. SP (at the doses ranging from 10 Ϫ6 M to 10 Ϫ12 M for 48 h) increased the proliferation of CCA cell lines compared with their basal values (Fig. 3A) . However, no significant effects for SP were observed in nonmalignant cholangiocytes (data not shown). The stimulatory effect of SP (at 10 Ϫ11 M at 48 h) on Mz-ChA-1 growth was blocked by the NK1R antagonist, L-733,060 (25 M) (Fig. 3B) ; at the same dose L-733,060 inhibited Mz-ChA-1 growth (Fig. 3B) . When CCA cell lines were treated with L-733,060 (at 5, 10, 25, 50, and 100 M) there was a dose-dependent decrease in cell proliferation compared with the relative basal values (Fig. 3C) . At the dose of 25 M, L-733,060 induced a significant decrease in the proliferation of selected CCA cell lines following incubation for 24 and 48 h (Fig. 3D) . By FACS analysis, we also show that L-733,060 decreased the proliferative activity of Mz-ChA-1 but not HIBEpiC cells (Fig. 3E) . The S phase of Mz-ChA-1 cells (treated with vehicle, basal value) displayed higher proliferation than HIBEpiC cells due to the high mitosis (Fig. 3E) . L-733,060 induced arrest of the G 0 /G 1 phase, and decreased the S phase of Mz-ChA-1 cells, indicating disruption of cell cycle progression in Mz-ChA-1 cells through inhibition of SP signaling; L-733,060 induced a significant increase in apoptosis in Mz-ChA-1 but not in HIBEpiC cells (Fig. 3E) .
To validate the overexpression of MME in Mz-ChA-1 cells (used in our in vivo studies in nu/nu nude mice) we have shown that Mz-MME cells express higher levels of the message for MME compared with vector transfected cells (Fig. 4A) . By MTS assays, there was reduced proliferation of Mz-MME compared with Mz-neg cell lines (Fig. 4B) .
Effects of administration of L-733,060 and overexpression of MME on the proliferation and expression of VEGF-A in
Mz-ChA-1 cells implanted in nu/nu nude mice. The NK1R inhibitor, L-733,060, had small effects on tumor growth at early time periods but at day 21 significantly decreased xeno- Mz-Neg Mz-MME OE mRNA expression (fold change)
CK-19 GAPDH
graft tumor volume throughout the measurement time period compared with the vehicle-treated xenograft tumors (Fig. 5A) . When implanted into the flanks of nu/nu nude mice, the tumors derived from Mz-MME cells grew to a lower extent (up to 21 days) than those originating from Mz-neg (Fig. 5B) . The expression of MME in Mz-MME cells was significantly different from that of Mz-neg cells both at the time of cell implantation (Fig. 4A) and at the time of tissue collection (Fig. 6B) .
There was decreased mRNA expression of PCNA, CK-19, and VEGF-A and increased expression of MME mRNA in the tumors from nu/nu nude mice treated with L-733,060 compared with their corresponding controls (Fig. 6A) . There was decreased mRNA expression of Tac1, NK1R, PCNA, CK-19, and VEGF-A and increased expression of MME mRNA in the tumors form Mz-MME cells compared with their corresponding controls (Fig. 6B) . No significant difference in body and liver weight, and liver to body weight ratio was observed among the four groups of nu/nu nude mice (Table 1) .
DISCUSSION
The major findings presented in this study relate to the dysregulation of the SP signaling system in CCA. We demonstrated that the expression of the SP-encoding gene Tac1 and the SP receptor NK1R are upregulated in human CCA tissues and cells. Furthermore, the expression of MME, the enzyme responsible for the deactivation of SP, is downregulated in CCA. Together, these results demonstrated enhanced SP production in human CCA cell lines and tumor tissue. Treatment of human CCA cell lines with recombinant SP significantly increased cell proliferation in vitro, an effect that was prevented by the NK1R antagonist L-733,060. Furthermore, strategies to block endogenous SP effects, namely treatment with L-733,060 alone or stable overexpression of MME, inhibited CCA proliferation in vitro and reduced tumor growth in vivo. These findings suggest that 1) dysregulation of SP signaling may be a key feature associated with the progression of CCA and 2) modulation of this pathway may be a novel approach for the development of effective adjunct therapies to treat this devastating cancer.
Similar to the observations that SP expression is upregulated in CCA, increased SP production and secretion have been discovered in many other types of cancers, including breast, pancreatic, and various gastric cancers (13, 16, 34) . However, to our knowledge, the data described in the present study represent new evidence for the role of the SP/NK1R axis in any primary liver tumor. Generally, regardless of the tumor type, high SP and NK1R expression correlated with poor prognosis factors such as tumor development, metastasis, and overall patient survival (13, 16, 34) .
Here, we present evidence that SP exerts growth-promoting effects on CCA cells in vitro, and blocking SP activity subsequently inhibits CCA cell proliferation in vitro and tumor growth in vivo. The mechanism by which SP is growth promoting in CCA is unknown; nevertheless, some of the functional effects of the upregulation of SP signaling in other cancers have been elucidated. For example, SP and NK1R are upregulated in HER2-positive breast tumors and are found to transactivate HER2 and EGFR; also, the inhibition of NK1R strongly decreased steady-state expression EGFR and HER2 (16) . Similarly, transactivation of EGFR is thought to be partly responsible for the mitogenic actions of SP in glioblastoma cells (9) . In addition, SP-mediated activation of the Ca 2ϩ /Src/ PKC␦/ERK1/2 pathway has been shown to enhance cancer cell proliferation (54) . Given that both EGFR activation and ERK1/2 activation are known to increase CCA cell proliferation and tumor growth (15, 44, 52, 55) , it is conceivable that SP may be exerting its mitogenic effects via a combination of these pathways. SP had been shown to mediate the antiapoptotic and proliferative responses of human colonocytes via activation of Akt signaling mechanisms (31) . Previous studies have shown that VEGF plays an important role in regulating both normal and neoplastic cholangiocyte proliferation (10, 17, 18) . SP has been shown to stimulate VEGF expression levels promoting angiogenesis and wound healing (29) . This finding may indicate an additional mechanism by which inhibition of SP signaling may decrease VEGF expression and subsequently CCA proliferation. Further studies are warranted to elucidate this potential mechanism mediated by SP.
The upregulation of SP/NK1R have also been observed in chronic liver diseases (19, 50) . Indeed, increased SP levels can be detected in the serum of both cholestatic patients and experimental cholestatic rodents (50) . Within the liver, SP has been shown to increase cholangiocyte proliferation during cholestasis via the cAMP-dependent phosphorylation of protein kinase A (19) . Furthermore, NK1R expression is observed in cholangiocytes and upregulated in a model of extrahepatic biliary obstruction. In addition, NK1R knockout mice have a dampened proliferative reaction to biliary hyperplasia (19) . Consistent with these observations, we found that treatment of HIBEpiC cells with recombinant SP also increased proliferation in vitro.
A study has shown that MME, the neutral endopeptidase responsible for cleaving and deactivating SP, is expressed in the bile canaliculi and interlobular ducts (7) . The expression of MME is downregulated during liver cirrhosis and hepatocellular carcinoma (38) . Furthermore, suppression of MME immunoreactivity has previously been described in extrahepatic bile duct cancers (49) . The data presented here demonstrate a suppression of MME expression in CCA, which supports the notion that MME expression may be downregulated in various types of liver cancers. Consistent with this concept, high MME expression in the tumor center or invasion front, but not in the lymph node metastases, was a favorable prognostic indicator in human bladder cancer (46) . In contrast, the expression of MME has been shown to decrease in noninvasive low-grade cancers compared with nonneoplastic tissue, but the expression increases again in invasive high-grade tumors (26) . This suggests that perhaps MME expression may be a reflection of the grade and invasiveness of the tumor in question. Indeed, MME expression was associated with a more aggressive phenotype in melanoma (48) , in colorectal carcinomas (23) , and in highgrade sarcoma tissue (12) . Interestingly, an explanation as to the disparity in the prognostic value of MME may lie in the predominant cell type within the tumor expressing MME. Specifically, non-small cell lung carcinoma with MME immunoreactivity in the stromal cells had worse prognostic impact decreased survival and disease free survival (21) . However, when MME expression was restricted to the epithelial cells, its expression level was a positive prognostic indicator correlating with an increased disease-free survival (21) . Taken together, these data indicate that the prognostic value of MME expression is dependent on the cell type expressing MME, the tumor grade, and the tumor type.
In conclusion, the data presented here indicate the existence of a dysregulated SP/NK1R pathway in human CCA compared with nonmalignant human biliary tissues and cells. Furthermore, there is a concomitant increase in NK1R expression in CCA. Conversely, the expression of MME, the enzyme responsible for deactivating SP, is suppressed in human CCA. Specific inhibition of SP function leads to a suppression of tumor growth in a xenograft model of CCA, suggesting that agents that modulate the bioavailability of SP may be the potential therapeutic tools for the treatment of this devastating human cancer. 
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